An Open-Label, Non-Randomized Phase II Study of Alvocidib (Flavopiridol) in Combination With Docetaxel in Refractory, Metastatic Pancreatic Cancer (NCI 6366)
Phase of Trial: Phase II
Latest Information Update: 08 Jul 2014
At a glance
- Drugs Alvocidib (Primary) ; Docetaxel (Primary)
- Indications Pancreatic cancer
- Focus Therapeutic Use
- 02 Nov 2007 Status changed from in progress to completed.
- 25 Oct 2007 Status changed from recruiting to in progress.
- 20 Oct 2006 New trial record.